Kawasaki Disease After Vaccination: Reports to the Vaccine Adverse Event Reporting System 1990-2007

*Source of age categories: References 24–28.
^†Including 1 classic case with age 5 yr, 1 atypical case with age 9 yr, and 4 possible cases with ages 5, 5, 8, and 12 yr.

Authors and Disclosures

Wei Hua, MD, PhD,* Hector S. Izurieta, MD, MPH,* Barbara Slade, MD,† Ermias D. Belay, MD,‡ Penina Haber, MPH,† Rosemary Tiernan, MD, MPH,§ Emily Jane Woo, MD, MPH,* John Iskander, MD, MPH,† M. Miles Braun, MD, MPH,* and Robert Ball, MD, MPH, ScM*

*Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), Rockville, MD; †Immunization Safety Office, Centers for Disease Control and Prevention (CDC), Atlanta, GA; ‡National Center for Zoonotic, Vector-Borne and Enteric Diseases, Coordinating Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, GA; and §Office of Vaccines Research and Review, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), Rockville, MD.

Address for correspondence
Wei Hua, MD, PhD, Vaccine Safety Branch, Division of Epidemiology, OBE, CBER, FDA, 1401 Rockville Pike, Suite 264S, HFM-222, Rockville, MD 20852–1448. E-mail: wei.hua@fda.hhs.gov.